| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Data | Frank Vinluan | 03/10/20 | Boston |
| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval | Frank Vinluan | 11/08/19 | New York |
| Thwarting Opposition, Bristol Gets Shareholder OK for $74B Celgene Buyout | Ben Fidler | 04/12/19 | New York |
| Celgene Files for FDA Approval of Blood Disease Drug | Frank Vinluan | 04/05/19 | New York |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More | Alex Lash | 11/26/18 | National |
| Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder | Frank Vinluan | 07/09/18 | Boston |
| Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing | Frank Vinluan | 06/28/18 | Boston |
| 15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) | Ben Fidler | 12/04/17 | National |
| East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More | Ben Fidler | 05/22/15 | Boston |
| East Coast Biotech Roundup: Celgene, Blueprint(s), Intarcia & More | Ben Fidler | 05/01/15 | Boston |
